PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma

Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions

(2021) Abolfazl Maghrouni et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma

(2020) Mai Takeuchi et al.   ANNALS OF HEMATOLOGY

The roles of programmed death ligand 1 in virus-associated cancers

(2020) Morvarid Golrokh Mofrad et al.   INFECTION GENETICS AND EVOLUTION

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

(2020) John Kuruvilla et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of PD-1 in Acute and Chronic Infection

(2020) Jil M. Jubel et al.   Frontiers in Immunology

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

(2020) V. Subbiah et al.   ANNALS OF ONCOLOGY

Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma

(2019) Yasushi Sawayama et al.   AMERICAN JOURNAL OF HEMATOLOGY

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

(2019) Laura M. McLane et al.   Annual Review of Immunology

Recent advances in the clinical development of immune checkpoint blockade therapy

(2019) Atefeh Ghahremanloo et al.   CELLULAR ONCOLOGY

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

(2019) Daniel A. Rauch et al.   BLOOD

A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

(2018) Olivier Hermine et al.   ADVANCES IN THERAPY

Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma

(2018) Yoshitaka Inoue et al.   BONE MARROW TRANSPLANTATION

Clinical Development of PD-1 Blockade in Hematologic Malignancies

(2018) Matthew J. Pianko et al.   CANCER JOURNAL

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals

(2018) Ayako Masaki et al.   CANCER SCIENCE

Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma

(2018) Yosuke Tanaka et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma

(2018) Mengxuan Zuo et al.   LEUKEMIA RESEARCH

PD-1 /PD-L1 checkpoint in hematological malignancies

(2018) O. Annibali et al.   LEUKEMIA RESEARCH

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy

(2018) Lee Ratner et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Inhibitor Therapy in Adult T-Cell Leukemia–Lymphoma

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Molecular targeting for treatment of human T-lymphotropic virus type 1 infection

(2018) Arash Soltani et al.   BIOMEDICINE & PHARMACOTHERAPY

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

(2018) Steven Horwitz et al.   LANCET

HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice

(2017) Rashida Ginwala et al.   Journal of Neuroimmune Pharmacology

Early Onset of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T-cell Leukemia/Lymphoma (ATL): Systematic Search and Review

(2017) Pedro D Oliveira et al.   JOURNAL OF TROPICAL PEDIATRICS

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients

(2017) Hojabr Kakavand et al.   MODERN PATHOLOGY

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

(2017) Tim Wartewig et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction: HTLV-1 bZIP Factor Enhances T-cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors

(2017) Haruka Kinosada et al.   PLoS Pathogens

IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways

(2017) Leila Sawada et al.   PLoS Pathogens

Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP

(2017) Yoshimi Enose-Akahata et al.   Frontiers in Microbiology

Comparative Analyses of Signature Genes in Acute Rejection and Operational Tolerance

(2017) Jeong-Woo Choi et al.   Immune Network

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma

(2016) H. Miyoshi et al.   BLOOD

2016 US lymphoid malignancy statistics by World Health Organization subtypes

(2016) Lauren R. Teras et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002

(2016) Takashi Ishida et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran

(2016) Houshang Rafatpanah et al.   JOURNAL OF MEDICAL VIROLOGY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients

(2016) Lucy B. M. Cook et al.   Retrovirology

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis

(2016) Wook Youn Kim et al.   VIRCHOWS ARCHIV

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

(2016) L Ratner et al.   Blood Cancer Journal

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Human T-cell leukemia virus-associated malignancy

(2016) Amanda R Panfil et al.   Current Opinion in Virology

Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study

(2016) Michinori Ogura et al.   Lancet Haematology

Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy

(2015) Locke J. Bryan et al.   BLOOD REVIEWS

Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study

(2015) Youko Suehiro et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Treatment of adult T-cell leukaemia/lymphoma

(2015) Lucy B. Cook et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Treg(s) in Cancer: Friends or Foe?

(2015) Dominik Wolf et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Integrated molecular analysis of adult T cell leukemia/lymphoma

(2015) Keisuke Kataoka et al.   NATURE GENETICS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options

(2015) Vijayakumar Velu et al.   Retrovirology

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

ST1926 repression of Tax: ATL targeted treatment?

(2014) R. Cesaire et al.   BLOOD

High incidence of CMV infection in adult T-cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation

(2014) N Nakano et al.   BONE MARROW TRANSPLANTATION

Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP

(2014) A Bazarbachi et al.   BONE MARROW TRANSPLANTATION

Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome

(2014) X. Ni et al.   CLINICAL CANCER RESEARCH

Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement

(2014) Nicole M. Chapman et al.   IMMUNOLOGIC RESEARCH

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia

(2013) D. Brusa et al.   HAEMATOLOGICA

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

(2013) L. Wang et al.   HAEMATOLOGICA

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

(2013) Nikolaos Patsoukis et al.   MOLECULAR AND CELLULAR BIOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor

(2013) Masao Matsuoka et al.   Current Opinion in Virology

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

(2012) Takashi Ishida et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vivo Blockade of the PD-1 Receptor Suppresses HIV-1 Viral Loads and Improves CD4+ T Cell Levels in Humanized Mice

(2012) B. E. Palmer et al.   JOURNAL OF IMMUNOLOGY

The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases

(2012) Gabriela Gualco et al.   MODERN PATHOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals

(2012) Yorifumi Satou et al.   Retrovirology

PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection

(2012) Sonia Norris et al.   VIRAL IMMUNOLOGY

Epidemiological Aspects and World Distribution of HTLV-1 Infection

(2012) Antoine Gessain et al.   Frontiers in Microbiology

Adult T-Cell Leukemia: A Review of Epidemiological Evidence

(2012) Masako Iwanaga et al.   Frontiers in Microbiology

How I treat adult T-cell leukemia/lymphoma

(2011) A. Bazarbachi et al.   BLOOD

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)

(2011) Claire E. Dearden et al.   BRITISH JOURNAL OF HAEMATOLOGY

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

Programmed death-1 (PD-1)/PD-1 ligand pathway–mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders

(2011) Tomohiro Kozako et al.   HUMAN IMMUNOLOGY

Oral tolerance

(2011) Howard L. Weiner et al.   IMMUNOLOGICAL REVIEWS

High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey

(2011) Houshang Rafatpanah et al.   JOURNAL OF CLINICAL VIROLOGY

Reduced Tim-3 Expression on Human T-lymphotropic Virus Type I (HTLV-I) Tax-specific Cytotoxic T Lymphocytes in HTLV-I Infection

(2011) Nashwa H. Abdelbary et al.   JOURNAL OF INFECTIOUS DISEASES

Long-term study of indolent adult T-cell leukemia-lymphoma

(2010) Y. Takasaki et al.   BLOOD

Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study

(2010) M. Hishizawa et al.   BLOOD

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

(2010) Xiangli Chen et al.   CANCER BIOLOGY & THERAPY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma

(2010) Lei Ni et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma

(2010) Kazuhito Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy

(2010) M Matsuoka et al.   ONCOGENE

Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis

(2010) Priya Kannian et al.   Viruses-Basel

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

(2008) T Kozako et al.   LEUKEMIA

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE